RT Journal Article
SR Electronic
T1 A hemagglutination-based, semi-quantitative test for point-of-care determination of SARS-CoV-2 antibody levels
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.01.21256452
DO 10.1101/2021.05.01.21256452
A1 Robert L. Kruse
A1 Yuting Huang
A1 Alyssa Lee
A1 Xianming Zhu
A1 Ruchee Shrestha
A1 Oliver Laeyendecker
A1 Kirsten Littlefield
A1 Andy Pekosz
A1 Evan M. Bloch
A1 Aaron A.R. Tobian
A1 Zack Z. Wang
YR 2021
UL http://medrxiv.org/content/early/2021/05/04/2021.05.01.21256452.abstract
AB Serologic, point-of-care tests to detect antibodies against SARS-CoV-2 are an important tool in the COVID-19 pandemic. The majority of current point-of-care antibody tests developed for SARS-CoV-2 rely on lateral flow assays, but these do not offer quantitative information. To address this, we developed a new method of COVID-19 antibody testing employing hemagglutination tested on a dry card, similar to that which is already available for rapid typing of ABO blood groups. A fusion protein linking red blood cells (RBCs) to the receptor-binding domain (RBD) of SARS-CoV-2 spike protein was placed on the card. 200 COVID-19 patient and 200 control plasma samples were reconstituted with O-negative RBCs to form whole blood and added to the dried protein, followed by a stirring step and a tilting step, 3-minute incubation, and a second tilting step. The sensitivity for the hemagglutination test, Euroimmun IgG ELISA test and RBD-based CoronaChek lateral flow assay was 87.0%, 86.5%, and 84.5%, respectively, using samples obtained from recovered COVID-19 individuals. Testing pre-pandemic samples, the hemagglutination test had a specificity of 95.5%, compared to 97.3% and 98.9% for the ELISA and CoronaChek, respectively. A distribution of agglutination strengths was observed in COVID-19 convalescent plasma samples, with the highest agglutination score (4) exhibiting significantly higher neutralizing antibody titers than weak positives (2) (p<0.0001). Strong agglutinations were observed within 1 minute of testing, and this shorter assay time also increased specificity to 98.5%. In conclusion, we developed a novel rapid, point-of-care RBC agglutination test for the detection of SARS-CoV-2 antibodies that can yield semi-quantitative information on neutralizing antibody titer in patients. The five-minute test may find use in determination of serostatus prior to vaccination, post-vaccination surveillance and travel screening.Competing Interest StatementR.L.K, Y.H., and Z.Z.W. are co-inventors on a patent application related to the fusion protein detection agent for SARS-CoV-2. The authors recruited Eldon Biologicals for the collaboration, but the data and conclusions here are fully the authors and independent from Eldon Biologicals. Beyond testing cards, no formal sponsored research funding was received from Eldon Biologicals.Funding StatementThis work was funded by the Johns Hopkins Department of Pathology Fred and Janet Sanfilippo Research Award (R.L.K), and partially supported by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease [grant R01DK106109] (Z.Z.W). Beyond testing cards, no formal sponsored research funding was received from Eldon Biologicals.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The parent studies of the collected patient samples were approved by The Johns Hopkins University School of Medicine Institutional Review Board (IRB00247886, IRB00250798, and IRB00091667). All samples were deidentified prior to testing in the current manuscript, and the original studies were conducted according to the ethical standards of the Helsinki Declaration of the World Medical Association.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the manuscript upon request to the authors.